SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Renal Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1510227
This article is part of the Research TopicReviews in Renal Pharmacology: 2024View all 12 articles
Effectiveness and safety of Shengxuening for treatment of renal anemia: A comprehensive systematic review and meta-analysis
Provisionally accepted
- 1China Aerospace Science & Industry Corporation 731 Hospital, Beijing, China
- 2Lanzhou University, Lanzhou, Gansu Province, China
- 3Beijing Hospital, Peking University, Beijing, Beijing Municipality, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
We aimed to evaluate the efficacy and safety of Shengxuening (SXN) in treating renal anemia by systematic review and meta-analysis.Methods: PubMed, Embase, the Cochrane Library, the ClinicalTrials.gov, SinoMed, the China Knowledge Network, the Wanfang Data Knowledge Service Platform and Technology Journal Database were searched from inception to September 2024 randomised controlled trials (RCTs) that compared SXN and other drugs or placebo in treating renal anemia. We used the Cochrane Bias Risk Tool to evaluate the risk of bias of all included RCTs, and used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) to evaluate the certainty of the evidence.Results: 31 RCTs involving 2372 patients were included. The efficiency of SXN was superior than the control group (included placebo group, other drugs group) in
Keywords: MD: 7.15 g/L, 95% CI: 5.68-8.62, P<0.001, GRADE: high, compared with other drugs: MD: 6.49 g/L, 95% CI: 3.50-9.47, P<0.001, GRADE: very low), serum ferritin (MD: 57.53 ng/mL, 95% CI: 29.70-85.36, P<0.001, GRADE: moderate, MD: 28.96 ng/mL, 95% CI: 1.88-56.04, P=0.04, GRADE: moderate) and transferrin saturation level (MD: 7.00%, 95% CI: 3.40-10.60, P=0.0001, GRADE: moderate, MD: 3.64%, 95% CI: 1.41-5.88, P=0.001, GRADE: moderate) Renal anemia, Shengxuening, Systematic review, Meta-analysis, Grade
Received: 12 Oct 2024; Accepted: 09 Jun 2025.
Copyright: © 2025 Zheng, Gu, Liu, Fu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Li Zheng, China Aerospace Science & Industry Corporation 731 Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.